Study guide
20.6 Malaria: Species, Life Cycle & Severe Disease
MRCP UK
Track your progress as you read
Finished sections get a check mark.
1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy
1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique
2 Clinical Sciences: Cellular, Genetic & Molecular Medicine
2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders
3 Clinical Sciences: Anatomy, Physiology & Immunology
3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions
4 Clinical Sciences: Statistics, Epidemiology & Trial Design
4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification
5 Clinical Pharmacology, Therapeutics & Toxicology
5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols
6 Cardiology: Coronary Artery Disease & Heart Failure
6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation
7 Cardiology: Arrhythmias, Valvular & Pericardial Disease
7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases
8 Respiratory Medicine: Airway & Parenchymal Lung Disease
8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis
9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders
9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing
10 Gastroenterology: Luminal Gastrointestinal Disease
10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia
11 Gastroenterology: Liver, Biliary & Pancreatic Disease
11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis
12 Endocrinology & Diabetes: Diabetes & Thyroid
12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules
13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium
13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease
14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease
14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases
15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance
15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis
16 Neurology: Cerebrovascular, Headache & Demyelinating Disease
16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases
17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease
17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders
18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease
18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies
19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy
19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease
20 Infectious Diseases & Tropical Medicine
20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites
21 Haematology: Anaemias & Red Cell Disorders
21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease
22 Haematology: Malignancy, Coagulation & Transfusion Medicine
22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions
23 Psychiatry in General Medicine
23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law
24 Geriatric Medicine
24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers
25 Dermatology
25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy
26 Oncology & Palliative Medicine
26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control
27 Medical Ophthalmology
27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease
20.6 Malaria: Species, Life Cycle & Severe Disease
Key Takeaways Explain This Topic AI
Severe falciparum malaria is defined by features including parasitaemia above 2%, impaired consciousness, acidosis, hypoglycaemia, renal failure, pulmonary oedema and haemoglobin below 70 g/L.
Intravenous artesunate is first-line treatment for severe malaria and is superior to quinine for mortality.
Radical cure of Plasmodium vivax and ovale needs primaquine to eradicate hypnozoites, and G6PD status must be checked first to avoid severe haemolysis.
Last updated: September 2026
Returning travellers presenting with acute febrile illnesses represent a high-stakes, time-critical domain in the MRCP(UK) Part 1 examination. Candidates must immediately recognize the laboratory and clinical hallmarks of severe Plasmodium falciparum malaria, differentiate malarial species, manage relapsing hypnozoite infections safely, identify enteric fever, diagnose arboviral and zoonotic fevers (dengue, leptospirosis), and delineate parasitic tissue infections (amoebic liver abscess and schistosomiasis).
1. Malaria: Species Biology, Life Cycle & Clinical Hallmarks
Malaria is transmitted via the nocturnal bite of an infected female Anopheles mosquito , which inoculates motile sporozoites into the human bloodstream. Sporozoites rapidly migrate to the liver, invading hepatocytes within 30 to 60 minutes to initiate asymptomatic asexual liver-stage development ( exo-erythrocytic schizogony ). After 5 to 16 days, infected hepatocytes rupture, releasing thousands of merozoites into the circulation to invade host erythrocytes, initiating cyclic erythrocytic schizogony .
Comparison of Human Plasmodium Species
Feature Plasmodium falciparum Plasmodium vivax Plasmodium ovale Plasmodium malariae Plasmodium knowlesi
Fever Periodicity Malignant tertian (irregular, continuous, or 48-hourly spikes) Benign tertian (regular 48-hour cycle) Benign tertian (regular 48-hour cycle) Quartan (regular 72-hour cycle) Quotidian (24-hour cycle)
Target Erythrocyte Age Infects red blood cells of all ages (unrestrained parasitaemia > 10 – 50 % > 10\text{–}50\% > 10 – 50% ) Reticulocytes / young RBCs only (parasitaemia < 2 % < 2\% < 2% ) Reticulocytes only (parasitaemia < 2 % < 2\% < 2% ) Older, senescent RBCs only (parasitaemia < 1 % < 1\% < 1% ) All RBC ages; zoonotic (macaque reservoir in Southeast Asia)
Dormant Liver Phase (Hypnozoites) Absent (no delayed relapses from liver) Present (dormant hypnozoites cause relapses months to years later) Present (dormant hypnozoites cause relapses months to years later) Absent (can cause recrudescence decades later from low blood load) Absent
Pathological Mechanism Cytoadherence & Sequestration in deep microvasculature via PfEMP-1 Benign; relies on Duffy antigen (Duffy-negative West Africans immune) Benign; oval RBCs with fimbriated ragged edges Associated with nephrotic syndrome (immune-complex MPGN) Rapid 24-hour replication; can cause severe malaria
Blood Film Morphology Delicate small ring forms, high count, appliqué forms , crescentic/banana-shaped gametocytes Large amoeboid trophozoites, enlarged RBCs, Schüffner's dots Oval enlarged RBCs, fimbriated edges, James's dots "Band form" trophozoites spanning across normal-sized RBC Ring forms resembling P. falciparum ; mature forms like P. malariae
Molecular Pathogenesis of Severe Falciparum Malaria
P. falciparum is uniquely lethal among human malaria species because of microvascular sequestration . As intra-erythrocytic trophozoites mature, the parasite synthesizes and exports Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP-1) to the host red cell surface, where it aggregates into electron-dense 'knobs'. PfEMP-1 acts as a high-affinity ligand that binds endothelial host receptors:
- CD36 (on microvascular endothelium)
- Intercellular Adhesion Molecule 1 (ICAM-1) (on cerebral microvascular endothelium)
- Endothelial Protein C Receptor (EPCR) (disrupts vascular barrier integrity and activates coagulation)
- Chondroitin Sulfate A (CSA) (on placental syncytiotrophoblast; placental malaria)
Sequestration of rigid, parasitized erythrocytes causes profound microvascular obstruction, capillary occlusion, localized endothelial ischaemia, and intense tissue dysoxia. In the cerebral microcirculation, this causes diffuse cerebral oedema, breakdown of the blood-brain barrier, and intracranial hypertension ( cerebral malaria ). Crucially, because late trophozoites and schizonts are sequestered in deep capillary beds, peripheral blood smears reflect only circulating young ring forms, occasionally underestimating the true systemic parasite burden .
- 2. Severe Falciparum Malaria vs. Uncomplicated Malaria
- Consensus Criteria for Severe Falciparum Malaria (WHO & UK Guidelines)
Severe malaria is defined by the presence of asexual P. falciparum parasitaemia alongside one or more of the following clinical or laboratory severity criteria :
High Parasitaemia: > 10 % > 10\% > 10% of circulating red cells parasitized in any patient, OR > 2 % > 2\% > 2% in non-immune individuals.
Impaired Consciousness / Cerebral Malaria: Glasgow Coma Scale (GCS) score < 11 < 11 < 11 in adults (or Blantyre Coma Score < 3 < 3 < 3 in children).
Severe Metabolic Acidosis: Standard base deficit > 8 mmol/L > 8\text{ mmol/L} > 8 mmol/L , arterial pH < 7.30 \text{pH} < 7.30 pH < 7.30 , plasma bicarbonate < 15 mmol/L < 15\text{ mmol/L} < 15 mmol/L , or venous blood lactate ≥ 5.0 mmol/L \ge 5.0\text{ mmol/L} ≥ 5.0 mmol/L (the strongest independent predictor of death).
Severe Normocytic Anaemia: Haemoglobin < 70 g/L < 70\text{ g/L} < 70 g/L ( < 7 g/dL < 7\text{ g/dL} < 7 g/dL ) or haematocrit < 20 % < 20\% < 20% .
Acute Kidney Injury: Serum creatinine > 265 μ mol/L > 265\ \mu\text{mol/L} > 265 μ mol/L ( > 3.0 mg/dL > 3.0\text{ mg/dL} > 3.0 mg/dL ) or blood urea > 20 mmol/L > 20\text{ mmol/L} > 20 mmol/L , or oliguria ( < 0.5 mL/kg/h < 0.5\text{ mL/kg/h} < 0.5 mL/kg/h ). Oliguric renal failure is caused by acute tubular necrosis secondary to microvascular obstruction, haemolysis, and haemoglobinuria ('blackwater fever').
Pulmonary Oedema / ARDS: Non-cardiogenic pulmonary oedema with severe hypoxaemia ( PaO 2 / FiO 2 < 300 \text{PaO}_2/\text{FiO}_2 < 300 PaO 2 / FiO 2 < 300 ).
Hypoglycaemia: Blood glucose < 2.2 mmol/L < 2.2\text{ mmol/L} < 2.2 mmol/L ( < 40 mg/dL < 40\text{ mg/dL} < 40 mg/dL ) (exacerbated by parasite glucose consumption and historically worsened by quinine-induced pancreatic beta-cell insulin secretion).
Circulatory Collapse / Algid Malaria: Systolic blood pressure < 90 mmHg < 90\text{ mmHg} < 90 mmHg with core-to-skin temperature gradient and cool peripheries.
Spontaneous Bleeding / Disseminated Intravascular Coagulation (DIC): Clinically apparent bleeding from venepuncture sites or gastrointestinal tract, with thrombocytopenia and prolonged prothrombin time.
Macroscopic Haemoglobinuria: Dark black/burgundy urine ('blackwater fever') reflecting massive intravascular haemolysis.
Jaundice: Total serum bilirubin > 50 μ mol/L > 50\ \mu\text{mol/L} > 50 μ mol/L ( > 3.0 mg/dL > 3.0\text{ mg/dL} > 3.0 mg/dL ) with concurrent evidence of other organ dysfunction.
- Evidence-Based Treatment Protocols [Confirmed Malaria Diagnosis]
- │
- ├─► [Severe Malaria Criteria Present?]
- │ │
- │ ├─► YES: Immediate IV Artesunate 2.4 mg/kg at 0, 12, 24h
- │ │ (Minimum 24h IV therapy until tolerating oral ACT)
- │ │
- │ └─► NO: Uncomplicated Malaria
- │
- └─► [Species Identification]
- │
- ├─► P. falciparum: Oral ACT (Artemether-lumefantrine [Riamet]
- │ or Dihydroartemisinin-piperaquine)
- │
- └─► P. vivax / P. ovale: Oral Chloroquine or ACT
- PLUS Mandatory G6PD Screening
- ──► If G6PD Normal: Oral Primaquine
- (14 days for hypnozoite cure)
First-Line Therapy for Severe Malaria: Intravenous Artesunate ( 2.4 mg/kg 2.4\text{ mg/kg} 2.4 mg/kg IV administered at 0, 12, and 24 hours , then once daily).
Evidence: Landmark multicentre randomized trials ( SEAQUAMAT in Asia and AQUAMAT in Africa) demonstrated that intravenous artesunate confers a 35 % 35\% 35% relative reduction in mortality compared to intravenous quinine. Artesunate acts significantly faster, clears ring-stage parasites before sequestration occurs, and does not induce hyperinsulinaemic hypoglycaemia or cardiac arrhythmias (QTc prolongation), which plague quinine therapy.
Duration: Intravenous artesunate must be administered for a minimum of 24 hours (at least 3 full doses), even if the patient can swallow earlier. Once 24 hours of IV therapy are completed and the patient can tolerate oral intake, switch to a complete 3-day course of an oral Artemisinin-based Combination Therapy (ACT).
First-Line Therapy for Uncomplicated P. falciparum Malaria: Oral Artemisinin-based Combination Therapy (ACT) :
Artemether with lumefantrine (Riamet: fixed-dose 6-dose regimen taken over 60 hours with fatty food), OR
Dihydroartemisinin-piperaquine (Eurartesim: once-daily dosing for 3 days).
Radical Hypnozoite Cure for P. vivax & P. ovale (Primaquine Protocol):
Blood-stage schizonts are cleared with oral chloroquine or ACT.
To eradicate dormant liver hypnozoites and prevent late relapse, oral primaquine ( 0.5 mg/kg/day 0.5\text{ mg/kg/day} 0.5 mg/kg/day for 14 days) must be administered.
MANDATORY PRE-TREATMENT G6PD SCREENING: Primaquine is a potent 8-aminoquinoline oxidant. In individuals with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency , primaquine triggers catastrophic acute intravascular haemolysis with haemoglobinuria and acute renal failure. Quantitative G6PD enzyme testing must be confirmed normal prior to the first dose of primaquine.